Pre–heart failure represents a critical but often overlooked stage where structural, functional or biomarker abnormalities exist before symptoms emerge. This editorial outlines how to distinguish pre-HF from general HF risk, reviews evidence-based screening strategies, and highlights targeted treatments including SGLT2 inhibitors, ACE inhibitors/ARBs and ICDs to prevent progression to symptomatic disease.